IQVIA艾昆纬：2025年癌症治疗中的抗体-药物偶联物-IQVIA方舟专利情报报告（英文版）

Antibody-drug conjugates (ADCs), which now account for approximately 20% of the clinical pipeline of antibodies for cancer, are comprised of three components: a monoclonal antibody chosen to target a specific receptor, a potent cytotoxic agent, and a linker that connects (conjugates) the antibody to the cytotoxin. From an efficacy perspective, there is substantial diversity of the drugs, linkers and drug-to-antibody ratios of the ADCs under development. From a safety perspective, the mechanis